Matthew Downham, PHD

Dr Downham studied for a bachelor of sciences degree (with honours) in industrial biology at London South Bank Polytechnic (UK) which included a placement with Boehringer Mannheim, now Roche (Germany). He then completed a PhD in biochemical engineering (Birmingham University, UK), a post-doctoral fellowship in bio-molecular sciences (Liverpool John Moores University, UK) and a post-graduate certificate in further/higher education (Bolton Institute, UK).
He joined the biopharmaceutical industry in 1997 and has worked for Protherics (UK), Bavarian Nordic (Germany), Morphosys (Germany) and Novartis Vaccines & Diagnostics (Italy). Throughout this time Dr Downham worked on preclinical and early clinical development of vaccine, antibody or enzyme therapies for infectious, hypertension, inflammatory and oncology indications. He was a certified European Registered Toxicologist (2010-2015) and has co-authored 29 publications/abstracts and 3 international patents.
Dr Downham joined the influenza vaccine franchise of AstraZeneca/Medimmune (UK) in February 2013 as an Associate Director, Flu Manufacturing Sciences & Technology within the Biopharmaceutical Development (R&D) department.